Loading...
XASXBIT
Market cap10mUSD
Jan 02, Last price  
0.02AUD
1D
5.88%
1Q
-5.26%
Jan 2017
-46.66%
Name

Biotron Ltd

Chart & Performance

D1W1MN
XASX:BIT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.33%
Rev. gr., 5y
-11.54%
Revenues
0k
-100.00%
0794,862402,45700000891,9511,722,4811,672,2651,548,1851,659,4791,622,5841,072,832803,0261,461,9451,558,5251,431,2830
Net income
-3m
L-1.61%
-1,883,575-2,198,973-3,234,004-1,882,093-1,776,099-1,872,244-1,907,527-2,378,052-3,850,745-3,085,814-2,723,221-3,004,303-3,093,405-1,593,645-1,611,799-3,575,959-3,194,347-2,781,083-3,492,766-3,436,524
CFO
-4m
L+8.47%
-1,710,695-1,787,424-3,645,129-1,622,319-1,892,243-1,858,310-1,968,741-2,287,852-3,090,611-2,975,848-2,719,700-3,080,907-2,833,497-1,842,011-1,497,891-3,081,822-3,407,597-2,436,048-3,290,035-3,568,566
Earnings
Feb 25, 2025

Profile

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
URL
https://www.biotron.com.au/
IPO date
Jan 24, 2001
Employees
4
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,431
-8.16%
1,559
6.61%
Cost of revenue
3,665
5,831
4,871
Unusual Expense (Income)
NOPBT
(3,665)
(4,400)
(3,313)
NOPBT Margin
Operating Taxes
(1,645)
(1,431)
5
Tax Rate
NOPAT
(2,020)
(2,969)
(3,313)
Net income
(3,437)
-1.61%
(3,493)
25.59%
(2,781)
-12.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
20
5,145
BB yield
-0.06%
-24.11%
Debt
Debt current
7
39
34
Long-term debt
7
13
86
Deferred revenue
Other long-term liabilities
20
Net debt
(433)
(3,986)
(1,675)
Cash flow
Cash from operating activities
(3,569)
(3,290)
(2,436)
CAPEX
(4)
Cash from investing activities
Cash from financing activities
(23)
5,533
(33)
FCF
(1,679)
(2,930)
(3,371)
Balance
Cash
393
3,984
1,741
Long term investments
54
54
54
Excess cash
447
3,967
1,717
Stockholders' equity
(244)
3,173
1,092
Invested Capital
7
45
97
ROIC
ROCE
1,547.21%
EV
Common stock shares outstanding
902,170
820,842
724,786
Price
0.04
46.15%
0.03
-57.38%
0.06
29.79%
Market cap
34,282
60.63%
21,342
-51.73%
44,212
29.79%
EV
33,850
17,356
42,537
EBITDA
(3,665)
(4,357)
(3,267)
EV/EBITDA
Interest
1
4
5
Interest/NOPBT